Vitamin C and cancer risk and treatment
References
- Maggini S., Wintergerst E.S., Beveridge S., Hornig D.H.: Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br. J. Nutr., 2007; 98: S29–S35.
- Padayatty S.J., Levine M.: Vitamin C: The known and the unknown and goldilocks. Oral Dis., 2016; 22: 463–493.
- Smirnoff N., Wheeler G.L.: Ascorbic acid in plants: Biosynthesis and function. Crit. Rev. Biochem. Mol. Biol., 2000; 35: 291–314.
- Vissers M.C., Das A.B.: Potential mechanisms of action for vitamin C in cancer: Reviewing the evidence. Front Physiol., 2018; 9: 809.
- González M.J., Miranda-Massari J.R., Mora E.M., Guzmán A., Riordan N.H., Riordan H.D., Casciari J.J., Jackson J.A., Román-Franco A.: Orthomolecular oncology review: Ascorbic acid and cancer 25 years later. Integr. Cancer Ther., 2005; 4: 32–44.
- Blaszczak W., Barczak W., Masternak J., Kopczyński P., Zhitkovich A., Rubiś B.: Vitamin C as a modulator of the response to cancer therapy. Molecules, 2019; 24: 453.
- Klimant E., Wright H., Rubin D., Seely D., Markman M.: Intravenous vitamin C in the supportive care of cancer patients: A review and rational approach. Curr. Oncol., 2018; 25: 139–148.
- Monti D.A., Mitchell E., Bazzan A.J., Littman S., Zabrecky G., Yeo C.J., Pillai M.V., Newberg A.B., Deshmukh S., Levine M.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One, 2012; 7: e29794.
- Wang H., Dutta B., Huang W., Devoe L.D., Leibach F.H., Ganapathy V., Prasad P.D.: Human Na+-dependent vitamin C transporter 1 (hSVCT1): Primary structure, functional characteristics and evidence for a non-functional splice variant. Biochim. Biophys. Acta, 1999; 1461: 1–9.
- Bánhegyi G., Benedetti A., Margittai E., Marcolongo P., Fulceri R., Németh C.E., Szarka A.: Subcellular compartmentation of ascorbate and its variation in disease states. Biochim. Biophys. Acta, 2014; 1843: 1909–1916.
- Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., Penalver M., Mancuso S., Scambia G.: GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer, 2001; 92: 1144–1150.
- Yun J., Mullarky E., Lu C., Bosch K.N., Kavalier A., Rivera K., Roper J., Chio I.I., Giannopoulou E.G., Rago C., et al.: Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science, 2015; 350: 1391–1396.
- Lv H., Wang C., Fang T., Li T., Lv G., Han Q., Yang W., Wang H.: Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2. NPJ Precis. Oncol., 2018; 2: 1.
- Chong T.L., Ahearn E.L., Cimmino L.: Reprogramming the epigenome with vitamin C. Front. Cell Dev. Biol., 2019; 7: 128.
- Howe G.R., Hirohata T., Hislop T.G., Iscovich J.M., Yuan J.M., Katsouyanni K., Lubin F., Marubini E., Modan B., Rohan T., et al.: Dietary factors and risk of breast cancer: Combined analysis of 12 case–control studies. J. Natl. Cancer Inst., 1990; 82: 561–569.
- Block G.: Vitamin C and cancer prevention: The epidemiologic evidence. Am. J. Clin. Nutr., 1991; 53: 270S–282S.
- Xi D.: Vitamin C in cancer therapeutics and metastasis. J. Orthop. Res. Ther., 2019; 10: 1127.
- Notani P.N., Jayant K.: Role of diet in upper aerodigestive tract cancers. Nutr. Cancer, 1987; 10: 103–113.
- Bo Y., Lu Y., Zhao Y., Zhao E., Yuan L., Lu W., Cui L., Lu Q.: Association between dietary vitamin C intake and risk of esophageal cancer: A dose-response meta-analysis. Int. J. Cancer, 2016; 138: 1843–1850.
- Fontham E.T., Pickle L.W., Haenszel W., Correa P., Lin Y.P., Falk R.T.: Dietary vitamins A and C and lung cancer risk in Louisiana. Cancer, 1988; 62: 2267–2273.
- Hua Y.F., Wang G.Q., Jiang W., Huang J., Chen G.C., Lu C.D.: Vitamin C intake and pancreatic cancer risk: A meta-analysis of published case-control and cohort studies. PLoS One, 2016; 11: e0148816.
- Lin P.H., Aronson W., Freedland S.J.: An update of research evidence on nutrition and prostate cancer. Urol. Oncol., 2019; 37: 387–401.
- Hoang B.V., Lee J., Choi I.J., Kim Y.W., Ryu K.W., Kim J.: Effect of dietary vitamin C on gastric cancer risk in the Korean population. World J. Gastroenterol., 2016; 22: 6257–6267.
- Myung S.K., Ju W., Kim S.C., Kim H., Korean Meta-analysis (KORMA) Study Group: Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: A meta-analysis. BJOG, 2011; 118: 1285–1291.
- Bai X.Y., Qu X., Jiang X., Xu Z., Yang Y., Su Q., Wang M., Wu H.: Association between dietary vitamin C intake and risk of prostate cancer: A meta–analysis involving 103,658 subjects. J. Cancer, 2015; 6: 913–921.
- Zhang S., Hunter D.J., Forman M.R., Rosner B.A., Speizer F.E., Colditz G.A., Manson J.E., Hankinson S.E., Willett W.C.: Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J. Natl. Cancer Inst., 1999; 91: 547–556.
- Fulan H., Changxing J., Baina W.Y., Wencui Z., Chunqing L., Fan W., Dandan L., Dianjun S., Tong W., Da P., Yashuang Z.: Retinol, vitamins A, C, and E and breast cancer risk: A meta-analysis and meta-regression. Cancer Causes Control, 2011; 22: 1383–1396.
- Cui Y., Shikany J.M., Liu S., Shagufta Y., Rohan T.E.: Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women’s Health Initiative Observational Study. Am. J. Clin. Nutr., 2008; 87: 1009-1018.
- Eichholzer M., Stähelin H.B., Gey K.F., Lüdin E., Bernasconi F.: Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int. J. Cancer, 1996; 66: 145–150.
- Loria C.M., Klag M.J., Caulfield L.E., Whelton P.K.: Vitamin C status and mortality in US adults. Am. J. Clin. Nutr., 2000; 72: 139–145.
- Lin J., Cook N.R., Albert C., Zaharris E., Gaziano J.M., Van Denburgh M., Buring J.E., Manson J.E.: Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial. J. Natl. Cancer Inst., 2009; 101: 14–23.
- Myung S.K., Kim Y., Ju W., Choi H.J., Bae W.K.: Effects of antioxidant supplements on cancer prevention: Meta-analysis of randomized controlled trials. Ann. Oncol., 2010; 21: 166–179.
- Park S.J., Myung S.K., Lee Y., Lee Y.J.: Effects of vitamin and antioxidant supplements in prevention of bladder cancer: A meta-analysis of randomized controlled trials. J. Korean Med. Sci., 2017; 32: 628–635.
- Jiang L., Yang K.H., Tian J.H., Guan Q.L., Yao N., Cao N., Mi D.H., Wu J., Ma B., Yang S.H.: Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: A meta-analysis of randomized controlled trials. Nutr. Cancer, 2010; 62: 719–727.
- Myung S.K., Yang H.J.: Efficacy of vitamin and antioxidant supplements in prevention of esophageal cancer: Meta-analysis of randomized controlled trials. J. Cancer Prev., 2013; 18: 135–143.
- Pais R.; Dumitraşcu D.L.: Do antioxidants prevent colorectal cancer? A meta–analysis. Rom. J. Intern. Med., 2013; 51: 152–163.
- Bjelakovic G., Nagorni A., Nikolova D., Simonetti R.G., Bjelakovic M., Gluud C.: Meta-analysis: Antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment. Pharmacol. Ther., 2006; 24: 281–291.
- Cadeau C., Fournier A., Mesrine S., Clavel-Chapelon F., Fagherazzi G., Boutron–Ruault M.C.: Vitamin C supplement intake and postmenopausal breast cancer risk: Interaction with dietary vitamin C. Am. J. Clin. Nutr., 2016; 104: 228–234.
- Chang Y.J., Myung S.K., Chung S.T., Kim Y., Lee E.H., Jeon Y.J., Park C.H., Seo H.G., Huh B.Y.: Effects of vitamin treatment or supplements with purported antioxidant properties on skin cancer prevention: A meta-analysis of randomized controlled trials. Dermatology, 2011; 223: 36–44.
- Katta R., Brown D.N.: Diet and skin cancer: The potential role of dietary antioxidants in nonmelanoma skin cancer prevention. J. Skin Cancer, 2015; 2015: 893149.
- Jamison J.M., Gilloteaux J., Taper H.S., Calderon P.B., Summers J.L.: Autoschizis: A novel cell death. Biochem. Pharmacol., 2002; 63: 1773–1783.
- Shenoy N., Bhagat T., Nieves E., Stenson M., Lawson J., Choudhary G.S., Habermann T., Nowakowski G., Singh R., Wu X., et al.: Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J., 2017; 7: e587.
- Capone M., Giannarelli D., Mallardo D., Madonna G., Festino L., Grimaldi A.M., Vanella V., Simeone E., Paone M., Palmieri G., et al.: Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunother. Cancer, 2018; 6: 74.
- McMillan D.C.: Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care, 2009; 12: 223–226..
- Kedzierska M., Olas B., Wachowicz B., Glowacki R., Bald E., Czernek U., Szydłowska-Pazera K., Potemski P., Piekarski J., Jeziorski A.: Effects of the commercial extract of aronia on oxidative stress in blood platelets isolated from breast cancer patients after the surgery and various phases of the chemotherapy. Fitoterapia, 2012; 83: 310–317.
- Hoffman F.A.: Micronutrient requirements of cancer patients. Cancer, 1985; 55: 295–300.
- Mayland C.R., Bennett M.I., Allan K.: Vitamin C deficiency in cancer patients. Palliat. Med., 2005; 19: 17–20.
- Mikirova N., Casciari J., Riordan N., Hunninghake R.: Clinical experience with intravenous administration of ascorbic acid: Achievable levels in blood for different states of inflammation and disease in cancer patients. J. Transl. Med., 2013; 11: 191.
- De Loecker W., Janssens J., Bonte J., Taper H.S.: Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. II. Synergism with combined chemotherapy action. Anticancer Res., 1993; 13: 103–106.
- Nakagawa K.: Effect of chemotherapy on ascorbate and ascorbyl radical in cerebrospinal fluid and serum of acute lymphoblastic leukemia. Cell. Mol. Biol., 2000, 46: 1375–1381.
- Calderon P.B., Cadrobbi J., Marques C., Hong-Ngoc N., Jamison J.M., Gilloteaux J., Summers J.L., Taper H.S.: Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr. Med. Chem., 2002; 9: 2271–2285.
- Gilloteaux J., Jamison J.M., Neal D.R., Loukas M., Doberzstyn T., Summers J.L.: Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct. Pathol., 2010; 34: 140–160.
- Tareen B., Summers J.L., Jamison J.M., Neal D.R., McGuire K., Gerson L., Diokno A.: A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int. J. Med. Sci., 2008; 5: 62–67.
- Magrì A., Germano G., Lorenzato A., Lamba S., Chilà R., Montone M., Amodio V., Ceruti T., Sassi F., Arena S., et al.: High-dose vitamin C enhances cancer immunotherapy. Sci. Transl. Med., 2020; 12: eaay8707.
- Rayes R.F., Mouhanna J.G., Nicolau I., Bourdeau F., Giannias B., Rousseau S., Quail D., Walsh L., Sangwan V., Bertos N., et al.: Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects. JCI Insight, 2019; 5: e128008.
- Krakowska M., Debska-Szmich S., Czernek U., Czyzykowski R., Potemski P.: P-032 A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC). Ann. Oncol., 2016; 27: ii9.
- Hore T.A.: Modulating epigenetic memory through vitamins and TET: Implications for regenerative medicine and cancer treatment. Epigenomics, 2017; 9: 863–871.
- Guz J., Oliński R.: The role of vitamin C in epigenetic regulation. Postępy Hig. Med. Dośw., 2017; 71: 747–760.
- Sant D.W., Mustafi S., Gustafson C.B., Chen J., Slingerland J.M., Wang G.: Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. Sci. Rep., 2018; 8: 5306.
- Shenoy N., Bhagat T.D., Cheville J., Lohse C., Bhattacharyya S., Tischer A., Machha V., Gordon-Mitchell S., Choudhary G., Wong L.F., et al.: Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J. Clin. Invest., 2019; 129: 1612–1625.
- Luchtel R.A., Bhagat T., Pradhan K., Jacobs W.R. Jr., Levine M., Verma A., Shenoy N.: High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proc. Natl. Acad. Sci. USA, 2020; 117: 1666–1677.
- Rubis B., Luczak M.W., Krawic C., Zhitkovich A.: Vitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycin. Free Radic. Biol. Med., 2019; 136: 12–21.
- Buettner G.R., Moseley P.L.: Ascorbate both activates and inactivates bleomycin by free radical generation. Biochemistry, 1992; 31: 9784–9788.
- Prasad K.N., Hernandez C., Edwards-Prasad J., Nelson J., Borus T., Robinson W.A.: Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-α2b on human melanoma cells in culture by a mixture of vitamins. Nutr. Cancer, 1994; 22: 233–245.
- Chiang C.D., Song E.J., Yang V.C., Chao C.C.: Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem. J., 1994; 301: 759–764.
- Kurbacher C.M., Wagner U., Kolster B., Andreotti P.E., Krebs D., Bruckner H.W.: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett., 1996; 103: 183–189.
- Reddy V.G., Khanna N., Singh N.: Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem. Biophys. Res. Commun., 2001; 282: 409–415.
- Bhat S.H., Azmi A.S., Hanif S., Hadi S.M.: Ascorbic acid mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: A putative mechanism for anticancer properties. Int. J. Biochem. Cell Biol., 2006; 38: 2074–2081.
- Chen Q., Espey M.G., Sun A.Y., Pooput C., Kirk K.L., Krishna M.C., Khosh D.B., Drisko J., Levine M.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA, 2008; 105: 11105–11109.
- Schoenfeld J.D., Sibenaller Z.A., Mapuskar K.A., Wagner B.A., Cramer-Morales K.L., Furqan M., Sandhu S., Carlisle T.L., Smith M.C., Abu Hejleh T., et al.: O2⋅- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell, 2017; 31: 487–500.e8.
- Carr A.C., Cook J.: Intravenous vitamin C for cancer therapy – identifying the current gaps in our knowledge. Front Physiol., 2018; 9: 1182.
- Robitaille L., Mamer O.A., Miller W.H. Jr., Levine M., Assouline S., Melnychuk D., Rousseau C., Hoffer L.J.: Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism, 2009; 58: 263–269.
- Günes–Bayir A., Kiziltan H.S.: Palliative vitamin C application in patients with radiotherapy-resistant bone metastases: A retrospective study. Nutr. Cancer, 2015; 67, 921–925.
- Ma Y., Chapman J., Levine M., Polireddy K., Drisko J., Chen Q.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med., 2014; 6: 222ra18.
- Takahashi H., Mizuno H., Yanagisawa A.: High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe, 2012; 1: 49–53.
- Yeom C.H., Jung G.C., Song K.J.: Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J. Korean Med. Sci., 2007; 22: 7-11.
- Stephenson C.M., Levin R.D., Spector T., Lis C.G.: Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother. Pharmacol., 2013; 72: 139–146.
- Cameron E., Pauling L.: Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA, 1978; 75: 4538–4542.
- Murata A., Morishige F., Yamaguchi H.: Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int. J. Vitam. Nutr. Res. Suppl., 1982; 23: 103–113.
- Harris H.R., Bergkvist L., Wolk A.: Vitamin C intake and breast cancer mortality in a cohort of Swedish women. Br. J. Cancer, 2013; 109: 257–264.
- Vollbracht C., Schneider B., Leendert V., Weiss G., Auerbach L., Beuth J.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo, 2011; 25: 983–990.
- Hoffer L.J., Levine M., Assouline S., Melnychuk D., Padayatty S.J., Rosadiuk K., Rousseau C., Robitaille L., Miller W.H. Jr.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol., 2008; 19: 1969–1974.
- Kiziltan H.S., Bayir A.G., Demirtas M., Meral I., Taspinar O., Eris A.H., Aydin T., Mayadagli A.: Ascorbic-acid treatment for progressive bone metastases after radiotherapy: A pilot study. Altern. Ther. Health Med., 2014; 20: 16–20.
- Polireddy K., Dong R., Reed G., Yu J., Chen P., Williamson S., Violet P.C., Pessetto Z., Godwin A.K., Fan F., et al.: High Dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: Mechanisms and a phase I/IIa study. Sci. Rep., 2017; 7: 17188.
- Welsh J.L., Wagner B.A., van’t Erve T.J., Zehr P.S., Berg D.J., Halfdanarson T.R., Yee N.S., Bodeker K.L., Du J., Roberts L.J. 2nd, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother. Pharmacol., 2013; 71: 765–775.
- Pinkerton E., Good P., Gibbons K., Hardy J.: An open-label pilot study of oral vitamin C as an opioid-sparing agent in patients with chronic pain secondary to cancer. Support Care Cancer, 2017; 25: 341–343.
- Berenson J.R., Yellin O., Woytowitz D., Flam M.S., Cartmell A., Patel R., Duvivier H., Nassir Y., Eades B., Abaya C.D., et al.: Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen. Eur. J. Haematol., 2009; 82: 433–439.
- Riordan H.D., Casciari J.J., González M.J., Riordan N.H., Miranda-Massari J.R., Taylor P., Jackson J.A.: A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P. R. Health Sci. J., 2005; 24: 269–276.
- Nielsen T.K., Højgaard M., Andersen J.T., Jørgensen N.R., Zerahn B., Kristensen B., Henriksen T., Lykkesfeldt J., Mikines K.J., Poulsen H.E.: Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: A single-arm phase II trial. Transl. Androl. Urol., 2017; 6: 517–528.
- Zhao H., Zhu H., Huang J., Zhu Y., Hong M., Zhu H., Zhang J., Li S., Yang L., Lian Y., et al.: The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk. Res., 2018; 66: 1–7.
- Goel S., Agarwal S.B., Mandal A.K., Singhal K., Agarwal T.: Emerging role of ascorbic acid in the management of advanced breast carcinoma as a chemosensitizer. Asian J. Surg., 1999; 22: 333–336.
- Jeon Y., Park J.S., Moon S., Yeo J.: Effect of intravenous high dose vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial. Pain Res. Manag., 2016; 2016: 9147279.
- Creagan E.T., Moertel C.G., O’Fallon J.R., Schutt A.J., O’Connell M.J., Rubin J., Frytak S:. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N. Engl. J. Med., 1979; 301: 687–690.
- Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O’Connell M.J., Ames M.M.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N. Engl. J. Med., 1985; 312: 137-141.
- Zemskov V.S., Procopchuk O.L., Susak Y.M., Zemskov S.V., Hodysh Y.Y., Zemskova M.V.: Ukrain (NSC-631570) in the treatment of pancreas cancer. Drugs Exp. Clin. Res., 2000; 26: 179–190.
- Cameron E., Campbell A.: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem. Biol. Interact, 1974; 9: 285–315.
- Carr A.C., McCall C.: The role of vitamin C in the treatment of pain: New insights. J. Transl. Med., 2017; 15: 77.
- Jarosz M., Rychlik E., Stoś K., Charzewska J. (eds.): Normy żywienia dla populacji Polski i ich zastosowanie. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Warszawa 2020.
- Lykkesfeldt J., Poulsen H.E.: Is vitamin C supplementation beneficial? Lessons learned from randomised controlled trials. Br. J. Nutr., 2010; 103: 1251–1259.
DOI: https://doi.org/10.2478/ahem-2021-0031 | Journal eISSN: 1732-2693
Language: English
Page range: 987 - 1004
Submitted on: Sep 24, 2020
Accepted on: Jul 28, 2021
Published on: Jan 17, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2022 Sylwia Dębska-Szmich, Piotr Potemski, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.